LynparzaTM (olaparib) is a first‐in‐class PARP inhibitor (PARPi) that allows women with BRCA mutated (BRCAm) platinum‐sensitive relapsed high-grade serous ovarian cancer to extend progression‐free survival (PFS).1-3
Unfortunately, you are using an unsupported browser. Please use Google Chrome 52.0 or Internet Explorer 11 or later. Apologies for any inconvenience.
GB-6911 - June 2017